Matthew Boudreau, a chemistry PhD candidate in the CCIL Deputy Director Paul Hergenrother’s lab, has been awarded the prestigious F99/K00 grant from the National Cancer Institute (NCI). Boudreau’s research has centered around a novel therapeutic, ERSO, that successfully eradicates hormone-positive (ER+) breast cancer in multiple preclinical mouse models, and continues to be translated towards the clinic.
Read the rest of the story here.